


Morniflumate

Chemical Properties

CAS No. :	65847-85-0
Formula:	C19H20F3N3O3
Molecular Weight:	395.38
Storage:	Pure form: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Morniflumate (Niflam) is a nonsteroidal anti-inflammatory drug. It is used to treat inflammation.
Targets(IC50)	Others

Solubility Information

Solubility	DMSO: 60 mg/mL (151.75 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.06 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5292 mL	12.6461 mL	25.2921 mL
5 mM	0.5058 mL	2.5292 mL	5.0584 mL
10 mM	0.2529 mL	1.2646 mL	2.5292 mL
50 mM	0.0506 mL	0.2529 mL	0.5058 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cremonesi G, Cavalieri L. Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation. *J Int Med Res.* 2015 Jun;43(3):290-302. doi: 10.1177/0300060514567212. Epub 2015 Apr 28. Review. PubMed PMID: 25921871.

Cho HY, Park GK, Lee YB. Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. *Biomed Chromatogr.* 2013 Nov;27(11):1438-43. doi: 10.1002/bmc.2940. Epub 2013 May 30. PubMed PMID: 23722315.

Mero F, Nettis E, Aloia AM, Di Leo E, Ferrannini A, Vacca A. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs. *Int J Immunopathol Pharmacol.* 2013 Jan-Mar;26(1):247-50. PubMed PMID: 23527729.

Civelli M, Vigano T, Acerbi D, Caruso P, Giossi M, Bongrani S, Folco GC. Modulation of arachidonic acid metabolism by orally administered morniflumate in man. *Agents Actions.* 1991 Jul;33(3-4):233-9. PubMed PMID: 1659152.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481